Infliximab-induced hypoglycemia, a rare but relevant side effect.
Journal
Revista espanola de enfermedades digestivas
ISSN: 1130-0108
Titre abrégé: Rev Esp Enferm Dig
Pays: Spain
ID NLM: 9007566
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
pubmed:
5
2
2022
medline:
16
6
2022
entrez:
4
2
2022
Statut:
ppublish
Résumé
Tumor necrosis factor (TNF) inhibitors are part of the therapeutic arsenal for many immune-mediated diseases and, especially in inflammatory bowel disease (IBD), have led to a change in the management of this disease.
Identifiants
pubmed: 35118869
doi: 10.17235/reed.2022.8460/2021
doi:
Substances chimiques
Tumor Necrosis Factor Inhibitors
0
Tumor Necrosis Factor-alpha
0
Infliximab
B72HH48FLU
Adalimumab
FYS6T7F842
Types de publication
Letter
Langues
eng
Sous-ensembles de citation
IM